Aetiologies of low alkaline phosphatase in a Canadian Paediatric Tertiary Care Centre.
Alkaline phosphatase
Children
Laboratories
Paediatrics
Journal
Paediatrics & child health
ISSN: 1205-7088
Titre abrégé: Paediatr Child Health
Pays: England
ID NLM: 9815960
Informations de publication
Date de publication:
Dec 2023
Dec 2023
Historique:
received:
11
10
2022
accepted:
15
05
2023
pmc-release:
17
06
2024
medline:
19
4
2024
pubmed:
19
4
2024
entrez:
19
4
2024
Statut:
epublish
Résumé
Increasingly, laboratories flag low serum alkaline phosphatase (sALP) that are age-and sex-specific in paediatrics. The aim of this study was to report clinical manifestations of paediatric patients with age-and sex-specific low sALP, thereby increasing awareness of its potential aetiologies. This retrospective Canadian tertiary care paediatric hospital study assessed all sALP of ambulatory patients aged less than 18 years from 2015 to 2017. The hospital used a Beckman Coulter AU assay to measure sALP and compared values to the Canadian age-and sex-specific reference intervals from CALIPER. All children who had at least one subnormal age-and sex-specific sALP were evaluated. A review of medical charts of included patients was performed and demographic characteristics, medical history and diagnosis were collected, and categorized under groups of medical disorders. Of 11,874 included patients, 1,001 patients (9.2%) had low sALP. Of those, 48% (485/1,001) had transient low sALP activity and 9.6% (96/1,001) had persistently low sALP. Prolonged immobilization and inflammatory bowel disease represented the main aetiologies for persistently low sALP. Interestingly, 13.5% (13/96) of patients with persistently low sALP had no apparent aetiology. Our results report aetiologies of low sALP in a Canadian paediatric population using age-and sex-specific Canadian reference ranges. This study highlights that healthcare providers should be aware that a low sALP may have clinical significance and should be repeated if warranted based on further clinical assessment.
Identifiants
pubmed: 38638542
doi: 10.1093/pch/pxad031
pii: pxad031
pmc: PMC11022865
doi:
Types de publication
Journal Article
Langues
eng
Pagination
483-488Informations de copyright
© The Author(s) 2023. Published by Oxford University Press on behalf of the Canadian Paediatric Society. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.
Déclaration de conflit d'intérêts
MB and TF report that they are employee of AZ—Alexion Rare Disease. The authors have no other disclosures.
Références
J Pediatr. 2021 Feb;229:54-60.e2
pubmed: 32980379
Orphanet J Rare Dis. 2021 Oct 28;16(1):452
pubmed: 34711245
Clin Chem. 1995 Apr;41(4):515-8
pubmed: 7720239
Best Pract Res Clin Rheumatol. 2008 Mar;22(1):113-27
pubmed: 18328985
J Pediatr. 2016 May;172:181-186.e1
pubmed: 26896157
J Pediatr Endocrinol Metab. 2021 Aug 24;34(12):1559-1566
pubmed: 34428361
Calcif Tissue Int. 2016 Apr;98(4):398-416
pubmed: 26590809
Calcif Tissue Int. 2020 Jun;106(6):608-615
pubmed: 32088736
J Clin Res Pediatr Endocrinol. 2018 Mar 1;10(1):19-24
pubmed: 28766503
Bone. 2017 Sep;102:15-25
pubmed: 28238808
J Pediatr Endocrinol Metab. 2021 Sep 22;35(2):169-178
pubmed: 34551461
Pediatr Endocrinol Rev. 2013 Jun;10 Suppl 2:380-8
pubmed: 23858621
Clin Chem. 2012 May;58(5):854-68
pubmed: 22371482
Methods Mol Biol. 2013;1053:27-51
pubmed: 23860646
Ann Clin Biochem. 2021 Jul;58(4):335-341
pubmed: 33601892
Osteoporos Int. 2014 Feb;25(2):519-23
pubmed: 23912555
Ann Clin Biochem. 2023 Mar;60(2):92-99
pubmed: 36348502
Clin Biochem. 2015 Nov;48(16-17):1151-9
pubmed: 25979809